[2][3][4] He is a tenured Professor of Radiology at the University of Southern California (USC), holding joint appointments in Urology, Radiation Oncology, and Biomedical Engineering.
He traced its origins back to post-World War II and its growing significance in diagnostics and therapy, with applications in neurology, cardiology, oncology and infectious and inflammatory diseases.
[11] Jadvar contributed to the pivotal Lancet Oncology Commission report, which identified and expanded on strategic priorities for advancing cancer research and treatment in the United States.
The report pointed out to innovative approaches in cancer prevention, early detection, treatment, and survivorship, emphasizing the role of interdisciplinary collaboration and technologies like genomic and immune profiling.
Jadvar's expertise, particularly in molecular imaging and radiopharmaceutical therapy, played a significant role in shaping actionable recommendations, at the end of the report; aimed at improving patient outcomes and encouraging global collaboration in cancer control.
Under his leadership, the task force proposed alternative and innovative training pathways to ensure comprehensive education, adapt to evolving clinical demands, and maintain nuclear medicine's independence while enhancing interdisciplinary cooperation.
The committee advises the U.S. Nuclear Regulatory Commission (NRC) on technical issues related to the regulation of medical uses of radioactive material.
Jadvar’s research focuses on positron emission tomography, translational molecular imaging, and radiopharmaceutical therapy, particularly in prostate cancer.